Armisarte (previously Pemetrexed Actavis)
What Armisarte (previously Pemetrexed Actavis) is used for
Malignant pleural mesothelioma Pemetrexed in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancer Pemetrexed in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. Pemetrexed is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Armisarte (previously Pemetrexed Actavis)
- Active substance
- pemetrexed
- Disease area
- Carcinoma, Non-Small-Cell Lung; Mesothelioma
- Medicine group
- Antineoplastic agents
- ATC code
- L01BA04
- Marketing authorisation holder
- Actavis Group PTC ehf
- Authorised in the EU since
- 2016
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Armisarte (previously Pemetrexed Actavis) used for?
Malignant pleural mesothelioma Pemetrexed in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancer Pemetrexed in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in…
What is the active substance in Armisarte (previously Pemetrexed Actavis)?
Armisarte (previously Pemetrexed Actavis) contains pemetrexed.
Who makes Armisarte (previously Pemetrexed Actavis)?
The EU marketing authorisation holder is Actavis Group PTC ehf.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU